ArticleBMC ophthalmology2026
From infection to infarction: cytomegalovirus retinitis complicated by retinal ischemia and vitreous hemorrhage in the setting of JAK inhibition - a case report.
Article in BMC ophthalmology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundCytomegalovirus (CMV) retinitis has been increasingly reported in patients receiving Janus kinase (JAK) inhibitors, yet vision-threatening ischemic complications in this population remain poorly characterized. Immune recovery uveitis (IRU) and cystoid macular edema (CME) are recognized post-infectious sequelae, but delayed retinal ischemia and hemorrhage in the setting of JAK inhibition are uncommon. We present a case that illustrates these complications in a patient on upadacitinib for rheumatoid arthritis. CASE PRESENTATION: An 81-year-old woman with rheumatoid arthritis on upadacitinib for approximately one year and long-term hydroxychloroquine presented with decreased vision and floaters in her left eye. Examination revealed vitritis, focal hemorrhagic retinitis, and an epiretinal membrane without CME. Anterior chamber paracentesis confirmed CMV infection via aqueous humor polymerase chain reaction, guiding prompt antiviral therapy. She received oral valganciclovir and alternating intravitreal ganciclovir and foscarnet, though systemic therapy was later discontinued due to leukopenia. After cessation of upadacitinib and hydroxychloroquine, the retinitis stabilized, but she developed IRU with new-onset CME. Weeks later, she presented with a dense vitreous hemorrhage without retinal tears or detachment. Fluorescein angiography revealed temporal retinal ischemia remote from the original retinitis. Intravitreal bevacizumab led to improvement in both CME and hemorrhage. Pan-retinal photocoagulation is planned to reduce the risk of recurrent hemorrhage.
conclusionsThis case illustrates CMV retinitis in the setting of JAK inhibition complicated by delayed retinal ischemia and vitreous hemorrhage arising remote from the original retinitis. Although ischemic vasculopathy is a recognized complication of CMV retinitis among non-HIV immunosuppressed patients, such sequelae have been infrequently documented in JAK inhibitor-associated cases. Ophthalmologists should maintain a high index of suspicion for CMV retinitis in this emerging population and continue close surveillance for delayed ischemic complications even after apparent disease stabilization.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.